Grace Therapeutics (GRCE) Retained Earnings (2017 - 2026)

Grace Therapeutics has disclosed Retained Earnings across 10 years of filings, most recently posting $298.5 million for Q2 2026.

• In Q2 2026, Retained Earnings rose 1.66% year-over-year to $298.5 million; the TTM figure through Jun 2026 stood at $298.5 million (up 1.66% YoY), while the FY2026 annual figure was $298.4 million, up 1.73% from the prior year.
• Retained Earnings came in at $298.5 million for Q2 2026 at Grace Therapeutics, roughly flat from $298.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $298.5 million in Q2 2026 to a low of -$217.2 million in Q3 2024.
• Average Retained Earnings over 5 years is $24.4 million, with a median of -$158.1 million recorded in 2022.
• Year-over-year, Retained Earnings fell 27.23% in 2023 and soared 240.67% in 2024.
• Over 5 years, Retained Earnings stood at -$169.2 million in 2022, then slipped by 22.92% to -$208.0 million in 2023, then soared by 234.4% to $279.5 million in 2024, then advanced by 6.7% to $298.2 million in 2025, then grew by 0.1% to $298.5 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $298.5 million in Q2 2026, $298.4 million in Q1 2026, and $298.2 million in Q4 2025.